Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience

Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience

Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) is a severe and fatal manifestation of systemic autoimmune disorders. Therapies rely on immunomodulators but their efficacy in ILD progression remains uncertain. Nintedanib, an antifibrotic agent that slows pulmonary function decline, has...

Full description

Bibliographic Details
Main Authors: Maria Boutel, Afroditi Boutou, Georgia Pitsiou, Alexandros Garyfallos, Theodoros Dimitroulas
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Diagnostics
Subjects:
connective tissue interstitial lung disease
CTD-ILD
ILD
nintedanib
real-world data
Online Access:https://www.mdpi.com/2075-4418/13/7/1221

Internet

https://www.mdpi.com/2075-4418/13/7/1221

Similar Items